20 November 2019
GuildLink is pleased to announce it has updated GuildCare NG’s chronic obstructive pulmonary disease (COPD) Screening Program with Bird Healthcare’s respiratory testing and screening device AirNext.
“COPD is a serious long-term disease that affects almost 14% of older Australians and is one of the top five leading causes of death in Australia ,” said GuildLink CEO Arun Sharma, “Pharmacists are at the forefront of helping patients manage their COPD. Not only do they ensure patients understand how to use inhalers correctly and help manage their medicines; they also provide regular lung function screening as part of in-pharmacy professional services.”
The palm-sized AirNext Spirometer is one of the world’s first bluetooth-enabled spirometers, allowing users to undertake highly precise on-the-spot lung function assessments. The hand-held device also runs on just two replaceable AA batteries. AirNext’s software provides detailed instructions on how to perform a lung function test; as well as auto-interpretation and longitudinal lung health monitoring. AirNext Spirometer testing is conducted within ATS / ERS / ISO spirometry guidelines.
To access the resulting AirNext lung function report, pharmacists and users are required to download the accompanying Air MD Professional Spirometry app, by NuvoAir AB – available via the Apple Store and Google Play Store.
“AirNext connects to a variety of mobile devices and delivers its report in a PDF format which can be easily printed, emailed or uploaded into an electronic health record. The digital access of this report will make it easier for pharmacists, healthcare professionals and patients to make more informed healthcare decisions,” explained Sharma.
- Click for more information about GuildCare NG’s COPD Screening Program or please talk to your GuildLink State Manager.
- For more information about World COPD Day, please visit Lung Foundation Australia
- Click for more information about Bird Healthcare’s AirNext Spirometer.
 AirNext allows pharmacists to measure FEV1, FEV6, FEV1%, FVC, FVC%, FEV1/FVC ratio, PEF FEF and more. It provides 2012-GLI predicted values with LLN and Z-score values to infer lung function severity. Reports include on-screen visualisation of flow volume loops with data analysis along with volume-time visualization
 Chronic obstructive pulmonary disease (COPD) is characterised by air low limitation in the lungs, which can lead to mild or severe shortness of breath that is not fully reversible even with treatment.
 Australian Institute of Health and Welfare (AIHW) National Health Survey (NHS) 2017–18; Chronic obstructive pulmonary disease (COPD); August 2019: COPD affects 13.7% of 65-75+ years old.
For GuildCare NG assistance, please contact GuildCare Support on 1300 859 328 or firstname.lastname@example.org
Media Inquiries: Communications and Marketing Manager Justine Lamond email@example.com | 02 8222 4446